EnerSpar Corp. (TSE:NRX) has released an update.
NurExone Biologic Inc. has reported encouraging first quarter 2024 financial results, including a net increase in cash and working capital due to successful fundraising and warrant exercises. The company has made significant progress in its regenerative medicine therapies, with preparations underway for human trials and a new OTCQB Venture Market listing to enhance investor visibility. R&D expenditures have decreased due to grants and reduced costs, while G&A expenses rose in support of public and investor relations.
For further insights into TSE:NRX stock, check out TipRanks’ Stock Analysis page.
